SAN DIEGO--(BUSINESS WIRE)--Cardium Therapeutics (OTCBB:CDTP) announced the start of patient recruitment for its Phase 3 clinical trial (AWARE) to evaluate the therapeutic effects of Cardium’s lead product candidate, Generx™ (alferminogene tadenovec, Ad5FGF-4), in women for the potential treatment of myocardial ischemia. Myocardial ischemia, insufficient blood flow within the heart muscle, gives rise to angina associated with coronary heart disease. Generx represents a new therapeutic class of biologics designed to promote angiogenesis, a natural process of blood vessel growth within the heart muscle, following a one-time intracoronary administration from a standard cardiac infusion catheter.
